SG11201808630WA - Humanized anti-pacap antibodies and uses thereof - Google Patents
Humanized anti-pacap antibodies and uses thereofInfo
- Publication number
- SG11201808630WA SG11201808630WA SG11201808630WA SG11201808630WA SG11201808630WA SG 11201808630W A SG11201808630W A SG 11201808630WA SG 11201808630W A SG11201808630W A SG 11201808630WA SG 11201808630W A SG11201808630W A SG 11201808630WA SG 11201808630W A SG11201808630W A SG 11201808630WA
- Authority
- SG
- Singapore
- Prior art keywords
- wvrqapgkglewig
- washington
- syymt
- pacap
- fidaggdayyaswakg
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
- C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/575—Hormones
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property -, Organization 11111111011110111010101111101011111011101111111101011111001101111101111011111 International Bureau ... .... ..Yjd ..... ....!;,,,' (10) International Publication Number (43) International Publication Date WO 2017/181039 Al 19 October 2017(19.10.2017) WIPO I PCT (51) International Patent Classification: (US). SMITH, Jeffrey, T.L.; 42 Abington, Malahide, C07K 16/26 (2006.01) C07K 19/00 (2006.01) Dublin, 13 (IE). LATHAM, John, A.; 2409 10th Avenue C07K 16/18 (2006.01) A61K 39/00 (2006.01) W., Seattle, Washington 98119 (US). KARASEK, Charlie; 1221 Minor Avenue, Apt. 709, Seattle, Washing- (21) International Application Number: PCT/US2017/027669 ton 98101 (US). MULLIGAN, Jenny; 9512 53rd Avenue N.E., Lake Forest Park, Washington 98155 (US). SCAL- (22) International Filing Date: LEY-KIM, Michelle; 3002 19th Avenue S., Seattle, 14 April 2017 (14.04.2017) Washington 98144 (US). STEWART, Erica; 1030 NE (25) Filing Language: English 103rd Street, Seattle, Washington 98125 (US). RUBIN, Vanessa Lisbeth; 2230 N. 106th Street, Apt. 205, Seattle, (26) Publication Language: English Washington 98133 (US). BILLGREN, Jens J.; 7309 Sand Point Way N.E., #B948, Seattle, Washington 98115 (US). (30) Priority Data: 62/322,939 15 April 2016 (15.04.2016) US (74) Agents: TESKIN, Robin, L. et al.; Leclair Ryan, P.C., In- 62/322,957 15 April 2016 (15.04.2016) US tellectual Property Department, 2318 Mill Road, Suite 62/323,495 15 April 2016 (15.04.2016) US 1100, Alexandria, Virginia 22314 (US). 62/323,573 15 April 2016 (15.04.2016) US (81) Designated States (unless otherwise indicated, for every 62/366,902 26 July 2016 (26.07.2016) US kind of national protection available): AE, AG, AL, AM, 62/408,347 14 October 2016 (14.10.2016) US AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, (71) Applicant: ALDER BIOPHARMACEUTICALS, INC. BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, [US/US]; 11804 North Creek Parkway South, Bothell, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, Washington 98011 (US). HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, _ (72) Inventors: LOOMIS, Maria-Cristina; 4807 196th Street MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, Bothell, SE, Washington 98012 (US). GAR- NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, CIA-MARTINEZ, Leon, F.; 4926 214th Street SE, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, Woodinville, Washington 98072 (US). DUTZAR, Ben- TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, = jamin, H.; 511 NE 81st Street, Seattle, Washington 98115 ZA, ZM, ZW. (US). ALLISON, Daniel, S.; 19223 55th Avenue N.E., Lake Forest Park, Washington 98155 HENDRIX, (84) Designated States (unless otherwise indicated, for every (US). Katherine, Lee; 11804 North Creek Parkway South, kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, Bothell, Washington 98011 (US). OJALA, Ethan; 14310 Nevers Road, Snohomish, Washington 98290 FAN, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, (US). Pei; 9815 NE 158th Street, Bothell, Washington 98011 TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, [Continued on next page] (54) Title: HUMANIZED ANTI-PACAP ANTIBODIES AND USES THEREOF Antibody Heavy chain Protein features Sequence Name FR1 CDR1 FR2 CDR2 AWN QSVEESGGRLVTPGTPLTLICTVSGIDLN SYYMT WVRQAPGKGLEWIG FIDAGGDAYYASWAKG Ab20 QSVEESGGRLVTPGTPLTLICTVSGIDLS SYYMS WVRQAPGKGLEWIG FIDIDGSAYYATWAKG Ab21 QSVEESGGRLVTPGTPLTLTCTVSGIDLS SYYMT WVRQAPGKGLEWVG FIDAGGSAYYATWAKG Ab22 QEQLVESGGGLVQPEGSLTLTCTASGFDFS SNAMC WVRQAPGKGLEWIG SIYNADGKNYYAIWAKG Ab23 QSVEESGGRLVTPGTPLTLTCTVSGFSLN NYAMS WVRQAPGKGLEWIG IMGVNDITYYASWAKG AblO.H EVQLVESGGGLVQPGGSLRLSCAASGIDLN SYYMT WVRQAPGKGLEWIG FIDAGGDAYYASWAKG Ab21.H EVQLVESGGGLVQPGGSLRLSCAASGIDLS SYYMT WVRQAPGKGLEWIG FIDAGGSAYIATWAKG Ab1O.H2 EVQLVESGGGLVQPGGSLRLSCAASGIDLN SYYMT WVRQAPGKGLEWIG FIDAGGDAYYASWAKG AblO.H3 EVQLVESGGGLVQPGGSLRLSCAASGIDLN SYYMT WVRQAPGKGLEWIG FIDAGGDAYYASWAKG AblO.H4 EVQLVESGGGLVQPGGSLRLSCAASGIDLN SYYMT WVRQAPGKGLEWIG FIDAGGDAYYASWAKG AblO.H5 EVQLVESGGGLVQPGGSLRLSCAASGIDLN SYYMT WVRQAPGKGLEWIG FIDAGGDAYYASWAKG AblO.H6 EVQLVESGGGLVQPGGSLRLSCAASGIDLN SYYMT WVRQAPGKGLEWIG FIDAGGDAYYASWAKG 11 Ab21.H2 EVQLVESGGGLVQPGGSLRLSCAASGIDLS SYYMT WVRQAPGKGLEWIG FIDAGGSAYYATWAKG Ab21.H3 EVQLVESGGGLVQPGGSLRLSCAASGIDLS SYYMT WVRQAPGKGLEWIG FIDAGGSAYYATWAKG Ab21. H4 EVQLVESGGGLVQPGGSLRLSCAASGIDLS SYYMT WVRQAPGKGLEWIG FIDAGGSAYYATWAKG C:r M Figure lA © - (57) : The present invention is directed to antibodies and antigen binding fragments thereof having binding specificity for w w PACAP. The antibodies and antigen binding fragments thereof comprise the sequences of the VH, VL, and CDR polypeptides de- I-1 ---- scribed herein, and the polynucleotides encoding them. Antibodies and antigen binding fragments described herein bind to and/or IN compete for binding to the same linear or conformational epitope(s) on human PACAP as an anti-PACAP antibody. The invention C contemplates conjugates of anti-PACAP antibodies and binding fragments thereof conjugated to one or more functional or detect - el able moieties. Methods of making said anti-PACAP antibodies and antigen binding fragments thereof are also contemplated. Other O embodiments of the invention contemplate using anti-PACAP antibodies, and binding fragments thereof, for the diagnosis, assess - ,.1 ment, and treatment of diseases and disorders associated with PACAP and conditions where antagonism of PACAP-related activit- ies, such as vasodilation, photophobia, mast cell degranulation, and/or neuronal activation, would be therapeutically beneficial. WO 2017/181039 Al MIDEDIMOMOIDEIRMEMOMMUMINOCIONVOIS DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, Published: LU, LV, MC, MK, MT, NL, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, NO, PL, PT, RO, RS, SE, w i t h international search report (Art. 21(3)) GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: — before the expiration of the time limit for amending claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) the — as to applicant's entitlement a patent (Rule 4.17(11)) to apply for and be granted with sequence listing part of description (Rule 5.2(a))
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662323495P | 2016-04-15 | 2016-04-15 | |
US201662322957P | 2016-04-15 | 2016-04-15 | |
US201662322939P | 2016-04-15 | 2016-04-15 | |
US201662323573P | 2016-04-15 | 2016-04-15 | |
US201662366902P | 2016-07-26 | 2016-07-26 | |
US201662408347P | 2016-10-14 | 2016-10-14 | |
PCT/US2017/027669 WO2017181039A1 (en) | 2016-04-15 | 2017-04-14 | Humanized anti-pacap antibodies and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201808630WA true SG11201808630WA (en) | 2018-10-30 |
Family
ID=60039434
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201808630WA SG11201808630WA (en) | 2016-04-15 | 2017-04-14 | Humanized anti-pacap antibodies and uses thereof |
SG10202109689Q SG10202109689QA (en) | 2016-04-15 | 2017-04-14 | Humanized anti-pacap antibodies and uses thereof |
SG10202109691U SG10202109691UA (en) | 2016-04-15 | 2017-04-14 | Anti-pacap antibodies and uses thereof |
SG11201808632YA SG11201808632YA (en) | 2016-04-15 | 2017-04-14 | Anti-pacap antibodies and uses thereof |
Family Applications After (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10202109689Q SG10202109689QA (en) | 2016-04-15 | 2017-04-14 | Humanized anti-pacap antibodies and uses thereof |
SG10202109691U SG10202109691UA (en) | 2016-04-15 | 2017-04-14 | Anti-pacap antibodies and uses thereof |
SG11201808632YA SG11201808632YA (en) | 2016-04-15 | 2017-04-14 | Anti-pacap antibodies and uses thereof |
Country Status (12)
Country | Link |
---|---|
US (8) | US10202435B2 (en) |
EP (2) | EP3426288A4 (en) |
JP (2) | JP7116685B2 (en) |
KR (2) | KR102444717B1 (en) |
CN (2) | CN109451728A (en) |
AU (3) | AU2017250815B2 (en) |
CA (2) | CA3020990A1 (en) |
IL (2) | IL262092B2 (en) |
MX (1) | MX2018012470A (en) |
SG (4) | SG11201808630WA (en) |
TW (2) | TW201738272A (en) |
WO (2) | WO2017181031A2 (en) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11844720B2 (en) | 2011-02-04 | 2023-12-19 | Seed Health, Inc. | Method and system to reduce the likelihood of dental caries and halitosis |
US11951140B2 (en) | 2011-02-04 | 2024-04-09 | Seed Health, Inc. | Modulation of an individual's gut microbiome to address osteoporosis and bone disease |
US11951139B2 (en) | 2015-11-30 | 2024-04-09 | Seed Health, Inc. | Method and system for reducing the likelihood of osteoporosis |
US11826388B2 (en) | 2013-12-20 | 2023-11-28 | Seed Health, Inc. | Topical application of Lactobacillus crispatus to ameliorate barrier damage and inflammation |
US11839632B2 (en) | 2013-12-20 | 2023-12-12 | Seed Health, Inc. | Topical application of CRISPR-modified bacteria to treat acne vulgaris |
US11833177B2 (en) | 2013-12-20 | 2023-12-05 | Seed Health, Inc. | Probiotic to enhance an individual's skin microbiome |
WO2016168757A1 (en) | 2015-04-16 | 2016-10-20 | Alder Biopharmaceuticals, Inc. | Use of anti-pacap antibodies and antigen binding fragments thereof for treatment, prevention, or inhibition of photophobia |
CA3020990A1 (en) | 2016-04-15 | 2017-10-19 | Alder Biopharmaceuticals, Inc. | Humanized anti-pacap antibodies and uses thereof |
KR20200104886A (en) * | 2017-12-28 | 2020-09-04 | 난징 레전드 바이오테크 씨오., 엘티디. | Antibodies and variants against PD-L1 |
WO2020264384A1 (en) | 2019-06-28 | 2020-12-30 | Amgen Inc. | Anti-cgrp receptor/anti-pac1 receptor bispecific antigen binding proteins |
CA3164445A1 (en) * | 2019-12-17 | 2021-06-24 | Biohaven Pharmaceutical Holding Company Ltd. | Intranasal pharmaceutical compositions of cgrp inhibitors |
US10822379B1 (en) | 2020-03-12 | 2020-11-03 | University of Pittsburgh—of the Commonwealth System of Higher Education | Molecules that bind to SARS-CoV-2 |
WO2021225161A1 (en) | 2020-05-08 | 2021-11-11 | 国立大学法人鹿児島大学 | Antidepressant/anxiolytic drug in which pac1 receptor antagonist is used |
AU2021385052A1 (en) * | 2020-11-19 | 2023-06-01 | Pfizer Ireland Pharmaceuticals | Compositions for improved delivery of cgrp inhibitors |
CN113237873B (en) * | 2021-03-31 | 2022-11-29 | 西南科技大学 | Reagent for rapidly detecting content of fentanyl and portable detection equipment |
CN113239599A (en) * | 2021-06-15 | 2021-08-10 | 江苏理工学院 | Intelligent tire wear life estimation method and device based on BP neural network |
US20230212281A1 (en) * | 2021-07-29 | 2023-07-06 | Cephalon, LLC | Compositions and methods for anti-pacap antibodies |
TW202330607A (en) * | 2021-09-30 | 2023-08-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | Antigen-binding molecules that specifically bind cgrp and pacap and the pharmaceutical use thereof |
Family Cites Families (113)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
US4419446A (en) | 1980-12-31 | 1983-12-06 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant DNA process utilizing a papilloma virus DNA as a vector |
US4579821A (en) | 1981-11-23 | 1986-04-01 | University Patents, Inc. | Control of DNA sequence transcription |
US4601978A (en) | 1982-11-24 | 1986-07-22 | The Regents Of The University Of California | Mammalian metallothionein promoter system |
US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
US4965199A (en) | 1984-04-20 | 1990-10-23 | Genentech, Inc. | Preparation of functional human factor VIII in mammalian cells using methotrexate based selection |
GB8516415D0 (en) | 1985-06-28 | 1985-07-31 | Celltech Ltd | Culture of animal cells |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
US4927762A (en) | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
GB8725529D0 (en) | 1987-10-30 | 1987-12-02 | Delta Biotechnology Ltd | Polypeptides |
US4956288A (en) | 1988-04-22 | 1990-09-11 | Biogen, Inc. | Method for producing cells containing stably integrated foreign DNA at a high copy number, the cells produced by this method, and the use of these cells to produce the polypeptides coded for by the foreign DNA |
EP0435911B1 (en) | 1988-09-23 | 1996-03-13 | Cetus Oncology Corporation | Cell culture medium for enhanced cell growth, culture longevity and product expression |
DE68925966T2 (en) | 1988-12-22 | 1996-08-29 | Kirin Amgen Inc | CHEMICALLY MODIFIED GRANULOCYTE COLONY EXCITING FACTOR |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5766883A (en) | 1989-04-29 | 1998-06-16 | Delta Biotechnology Limited | Polypeptides |
US5198542A (en) | 1989-06-20 | 1993-03-30 | Takeda Chemical Industries, Inc. | Dna encoding a pitvitary adenylate cyclase activating protein and use thereof |
FR2650598B1 (en) | 1989-08-03 | 1994-06-03 | Rhone Poulenc Sante | DERIVATIVES OF ALBUMIN WITH THERAPEUTIC FUNCTION |
US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
ATE210680T1 (en) * | 1990-03-17 | 2001-12-15 | Takeda Chemical Industries Ltd | ANTIBODIES TO HYPOPHYSIC ADENYL CYCLASE ACTIVATED PEPTIDE PACAP, HYBRIDOMAS AND DETERMINATION OF PACAP |
CA2090126C (en) | 1990-08-02 | 2002-10-22 | John W. Schrader | Methods for the production of proteins with a desired function |
US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
FR2669336B1 (en) | 1990-11-20 | 1993-01-22 | Adir | NOVEL OXAZOLO PYRIDINES DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. |
WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
LU91067I2 (en) | 1991-06-14 | 2004-04-02 | Genentech Inc | Trastuzumab and its variants and immunochemical derivatives including immotoxins |
FR2686899B1 (en) | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | NOVEL BIOLOGICALLY ACTIVE POLYPEPTIDES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. |
US5776427A (en) | 1992-03-05 | 1998-07-07 | Board Of Regents, The University Of Texas System | Methods for targeting the vasculature of solid tumors |
ES2091684T3 (en) | 1992-11-13 | 1996-11-01 | Idec Pharma Corp | THERAPEUTIC APPLICATION OF CHEMICAL AND RADIO-MARKED ANTIBODIES AGAINST THE RESTRICTED DIFFERENTIATION ANTIGEN OF HUMAN B-LYMPHOCYTES FOR THE TREATMENT OF B-CELL LYMPHOMA. |
US5604260A (en) | 1992-12-11 | 1997-02-18 | Merck Frosst Canada Inc. | 5-methanesulfonamido-1-indanones as an inhibitor of cyclooxygenase-2 |
EP0618291A3 (en) | 1993-02-26 | 1997-12-03 | Takeda Chemical Industries, Ltd. | PACAP receptor protein, method for preparing said protein, and use thereof |
US5409944A (en) | 1993-03-12 | 1995-04-25 | Merck Frosst Canada, Inc. | Alkanesulfonamido-1-indanone derivatives as inhibitors of cyclooxygenase |
AU6445894A (en) | 1993-03-19 | 1994-10-11 | Duke University | Method of treatment of tumors with an antibody binding to tenascin |
US5474995A (en) | 1993-06-24 | 1995-12-12 | Merck Frosst Canada, Inc. | Phenyl heterocycles as cox-2 inhibitors |
US5436265A (en) | 1993-11-12 | 1995-07-25 | Merck Frosst Canada, Inc. | 1-aroyl-3-indolyl alkanoic acids and derivatives thereof useful as anti-inflammatory agents |
US5643575A (en) | 1993-10-27 | 1997-07-01 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
US6399316B1 (en) | 1994-02-25 | 2002-06-04 | Takeda Chemical Industries, Ltd. | PACAP receptor protein, method for preparing said protein, and use thereof |
US5475995A (en) | 1994-05-16 | 1995-12-19 | Livingston; George G. | Truck spare tire locking rod |
US5616601A (en) | 1994-07-28 | 1997-04-01 | Gd Searle & Co | 1,2-aryl and heteroaryl substituted imidazolyl compounds for the treatment of inflammation |
DE69534530T2 (en) | 1994-08-12 | 2006-07-06 | Immunomedics, Inc. | FOR B-CELL LYMPHOMA AND LEUKEMIA SPECIMEN IMMUNOCONJUGATES AND HUMAN ANTIBODIES |
US5521213A (en) | 1994-08-29 | 1996-05-28 | Merck Frosst Canada, Inc. | Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2 |
US5593994A (en) | 1994-09-29 | 1997-01-14 | The Dupont Merck Pharmaceutical Company | Prostaglandin synthase inhibitors |
US5552422A (en) | 1995-01-11 | 1996-09-03 | Merck Frosst Canada, Inc. | Aryl substituted 5,5 fused aromatic nitrogen compounds as anti-inflammatory agents |
US5639780A (en) | 1995-05-22 | 1997-06-17 | Merck Frosst Canada, Inc. | N-benzyl indol-3-yl butanoic acid derivatives as cyclooxygenase inhibitors |
US5604253A (en) | 1995-05-22 | 1997-02-18 | Merck Frosst Canada, Inc. | N-benzylindol-3-yl propanoic acid derivatives as cyclooxygenase inhibitors |
US5510368A (en) | 1995-05-22 | 1996-04-23 | Merck Frosst Canada, Inc. | N-benzyl-3-indoleacetic acids as antiinflammatory drugs |
AU2663495A (en) | 1995-06-06 | 1996-12-24 | Human Genome Sciences, Inc. | Human g-protein receptor hcegh45 |
EP0941327A1 (en) | 1996-12-02 | 1999-09-15 | Human Genome Sciences, Inc. | Human g-protein receptor hcegh45, a pacap-like (g-protein pituitary adenylate cyclase activating polypeptide-like) receptor |
CA2324510A1 (en) | 1998-04-03 | 1999-10-14 | Millennium Pharmaceuticals, Inc. | Methods and compositions for the diagnosis and treatment of neuropsychiatric disorders |
US20020155533A1 (en) | 1998-11-30 | 2002-10-24 | Takeda Chemical | PACAP receptor protein, method for preparing said protein, and use thereof |
CZ296858B6 (en) | 1999-09-28 | 2006-07-12 | Bayer Corporation | Pituitary adenylate cyclase activating peptide (PACAP) receptor 3 (R3) agonists and their pharmacological methods of use |
US20020182729A1 (en) | 2001-01-11 | 2002-12-05 | Dicicco-Bloom Emanuel | Pituitary adenylate cyclase-activating polypeptide (PACAP) is an anti-mitogenic signal for selected neuronal precursors in vivo |
EP1436003B3 (en) | 2001-05-24 | 2012-03-14 | ZymoGenetics, Inc. | Taci-immunoglobulin fusion proteins |
EP1578354A4 (en) | 2002-03-26 | 2008-04-09 | Massachusetts Inst Technology | Targets, methods, and reagents for diagnosis and treatment of schizophrenia |
EP1507551A2 (en) | 2002-05-03 | 2005-02-23 | Neuronova AB | The functional role and potential therapeutic use of pacap, vip and maxadilan in relation to adult neural stem or progenitor cells |
WO2004006839A2 (en) | 2002-07-12 | 2004-01-22 | Bayer Pharmaceuticals Corporation | Pituitary adenylate cyclase activating peptide (pacap) receptor (vpac2) agonists and their pharmacological methods of use |
GB0216648D0 (en) | 2002-07-18 | 2002-08-28 | Lonza Biologics Plc | Method of expressing recombinant protein in CHO cells |
WO2004062684A2 (en) | 2003-01-16 | 2004-07-29 | D. Collen Research Foundation Vzw Onderwijs En Navorsing Campus Gasthuisberg K.U. Leuven | Treatment of thrombocytopenia with inhibitors of pacap |
ES2393555T3 (en) | 2003-10-22 | 2012-12-26 | Keck Graduate Institute | Methods for the synthesis of hetero-multimeric polypeptides in yeasts using a haploid mating strategy. |
US20080070239A1 (en) * | 2003-10-29 | 2008-03-20 | University Of Rochester | Detection of neureopeptides associated with pelvic pain disorders and uses thereof |
US20050129687A1 (en) | 2003-11-03 | 2005-06-16 | University Of Vermont And State Agricultural College | Use of inhibitors of PACAP receptor activity for treatment of overactive bladder and pelvic floor pain syndrome |
JP2007519739A (en) | 2004-01-27 | 2007-07-19 | バイエル・フアーマシユーチカルズ・コーポレーシヨン | Pituitary cell adenylate cyclase activating peptide (PACAP) receptor (VCAP2) agonists and methods for their pharmaceutical use |
JPWO2005094881A1 (en) * | 2004-03-30 | 2008-02-14 | 武田薬品工業株式会社 | Antibody medicine |
SG156680A1 (en) | 2004-10-27 | 2009-11-26 | Univ Florida | Adrenocorticotropic hormone analogs and related methods |
JPWO2006118328A1 (en) | 2005-04-28 | 2008-12-18 | 武田薬品工業株式会社 | Anti-degranulation agent |
RU2007147598A (en) | 2005-05-24 | 2009-06-27 | Эйвестаджен Лимитед,In (In) | METHOD FOR PRODUCING MONOCLONAL ANTIBODY TO CD20, INTENDED FOR TREATMENT OF B-CELL LYMPHOMA |
ATE458491T1 (en) | 2005-08-26 | 2010-03-15 | Univ Leland Stanford Junior | METHOD FOR TREATING HEADACHE BY ADMINISTRATION OF OXYTOCIN |
SI3045182T1 (en) | 2005-11-14 | 2018-08-31 | Teva Pharmaceuticals International Gmbh | Antagonist antibodies directed against calcitonin gene-related peptide for treating cluster headache |
EP2021463B1 (en) | 2006-05-19 | 2016-11-23 | Alder Biopharmaceuticals, Inc. | Culture method for obtaining a clonal population of antigen-specific b cells |
CA2660330A1 (en) | 2006-08-08 | 2008-02-14 | Kyoto University | Novel monoclonal antibody and use of the same |
EP2460828A3 (en) | 2006-11-10 | 2012-08-08 | UCB Pharma, S.A. | Antibodies and diagnostics |
US8466118B2 (en) * | 2007-04-23 | 2013-06-18 | Saint Louis University | Modulation of blood brain barrier protein expression |
EP2162469A4 (en) | 2007-05-21 | 2012-08-01 | Alderbio Holdings Llc | Novel rabbit antibody humanization methods and humanized rabbit antibodies |
US9056905B2 (en) | 2007-05-21 | 2015-06-16 | Alderbio Holdings Llc | Antibodies to TNF-α and use thereof |
KR101615715B1 (en) | 2007-05-21 | 2016-04-27 | 앨더바이오 홀딩스 엘엘씨 | Antibodies to il-6 and use thereof |
EP2009026A1 (en) | 2007-06-29 | 2008-12-31 | ThromboGenics N.V. | Anti-VPAC1 antibodies and their uses |
US20100104530A1 (en) * | 2007-06-26 | 2010-04-29 | Kathleen Freson | Anti-vpac1 antibodies and their uses |
AU2008275229B2 (en) | 2007-07-09 | 2014-11-06 | Genentech, Inc. | Prevention of disulfide bond reduction during recombinant production of polypeptides |
WO2009033489A2 (en) | 2007-09-11 | 2009-03-19 | Glostrup Hospital | Selective pacl inhibitors for use in the treatment of migraine and headaches |
EP2592147A1 (en) | 2007-10-12 | 2013-05-15 | F. Hoffmann-La Roche AG | Protein expression from multiple nucleic acids |
KR101671886B1 (en) * | 2008-06-25 | 2016-11-04 | 에스바테크 - 어 노바티스 컴파니 엘엘씨 | Stable and soluble antibodies inhibiting vegf |
DK2305300T3 (en) * | 2008-07-10 | 2016-06-06 | Toray Industries | Pharmaceutical composition for treatment and prevention of cancer |
US20110229423A1 (en) * | 2008-07-18 | 2011-09-22 | Galderma Research & Development | Pacap signaling pathway modulators for treating inflammatory skin diseases having a neurogenic component, notably rosacea, and compositions comprised thereof |
CA2742286C (en) * | 2008-11-12 | 2016-08-09 | F. Hoffmann-La Roche Ag | Pacap as a marker for cancer |
EP2374881A4 (en) | 2008-12-05 | 2013-03-13 | Chiome Bioscience Inc | Method for producing antibody directed against protein expressed on cell surface |
JO3382B1 (en) | 2008-12-23 | 2019-03-13 | Amgen Inc | Human cgrp receptor binding antibodies |
US8609097B2 (en) | 2009-06-10 | 2013-12-17 | Hoffmann-La Roche Inc. | Use of an anti-Tau pS422 antibody for the treatment of brain diseases |
ES2912569T3 (en) | 2009-08-28 | 2022-05-26 | Teva Pharmaceuticals Int Gmbh | Methods of treating visceral pain by administering antagonistic antibodies directed against calcitonin gene-related peptide |
JP5444088B2 (en) | 2010-03-31 | 2014-03-19 | 川崎重工業株式会社 | Valve plate and axial piston type hydraulic pump / motor equipped with the same |
JP5728574B2 (en) | 2010-07-21 | 2015-06-03 | アイメックImec | Method for determining active dopant profile |
US11214610B2 (en) | 2010-12-01 | 2022-01-04 | H. Lundbeck A/S | High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris |
KR20190112175A (en) * | 2010-12-01 | 2019-10-02 | 앨더바이오 홀딩스 엘엘씨 | Anti-ngf compositions and use thereof |
WO2012106407A2 (en) | 2011-02-01 | 2012-08-09 | The University Of Vermont And State Agricultural College | Diagnostic and therapeutic methods and products related to anxiety disorders |
US9855332B2 (en) | 2011-05-20 | 2018-01-02 | Alderbio Holdings Llc | Use of anti-CGRP antibodies and antibody fragments to treat diarrhea in subjects with diseases or treatments that result in elevated CGRP levels |
CN107602700B (en) | 2011-05-20 | 2021-12-17 | H.伦德贝克公司 | anti-CGRP compositions and uses thereof |
CA2836800A1 (en) | 2011-05-20 | 2012-11-29 | Alderbio Holdings Llc | Use of anti-cgrp antibodies and antibody fragments to prevent or inhibit photophobia or light aversion in subjects in need thereof, especially migraine sufferers |
US8524664B2 (en) | 2011-06-02 | 2013-09-03 | Colorado Seminary, Which owns and Operates The Univeristy of Denver | Methods of treating overproduction of cortisol using ACTH antagonist peptides |
EP2718277A4 (en) | 2011-06-06 | 2015-02-11 | Cardero Therapeutics Inc | Methods and compositions for treatment of mitochondrial toxicity |
US10112987B2 (en) | 2012-01-09 | 2018-10-30 | Icb International, Inc. | Blood-brain barrier permeable peptide compositions comprising a vab domain of a camelid single domain heavy chain antibody against an amyloid-beta peptide |
US9255154B2 (en) * | 2012-05-08 | 2016-02-09 | Alderbio Holdings, Llc | Anti-PCSK9 antibodies and use thereof |
TWI636064B (en) | 2013-03-15 | 2018-09-21 | 安美基公司 | Human pac1 antibodies |
JP6466397B2 (en) | 2013-03-15 | 2019-02-06 | アルダー・バイオファーマシューティカルズ・インコーポレーテッド | Protocol for identification and isolation of antigen-specific B cells and production of antibodies against the desired antigen |
EP3754012A1 (en) | 2013-03-15 | 2020-12-23 | Alder Biopharmaceuticals, Inc. | Antibody purification and purity monitoring |
UA118028C2 (en) | 2013-04-03 | 2018-11-12 | Рош Глікарт Аг | Bispecific antibodies specific for fap and dr5, antibodies specific for dr5 and methods of use |
JP2016539632A (en) * | 2013-10-25 | 2016-12-22 | ヌマブ アクチェンゲゼルシャフト | Bispecific constructs and their use in the treatment of various diseases |
EP3086846B1 (en) * | 2013-12-27 | 2019-02-20 | Dignity Health | Diagnosing alzheimer's disease |
EP3107569A4 (en) | 2014-02-20 | 2018-02-21 | Alder Biopharmaceuticals, Inc. | Anti-acth antibodies and use thereof |
WO2016168757A1 (en) * | 2015-04-16 | 2016-10-20 | Alder Biopharmaceuticals, Inc. | Use of anti-pacap antibodies and antigen binding fragments thereof for treatment, prevention, or inhibition of photophobia |
WO2017106578A1 (en) | 2015-12-15 | 2017-06-22 | Amgen Inc. | Pacap antibodies and uses thereof |
CA3020990A1 (en) * | 2016-04-15 | 2017-10-19 | Alder Biopharmaceuticals, Inc. | Humanized anti-pacap antibodies and uses thereof |
AR113022A1 (en) * | 2017-09-29 | 2020-01-15 | Lilly Co Eli | ANTI-PACAP ANTIBODY |
-
2017
- 2017-04-14 CA CA3020990A patent/CA3020990A1/en active Pending
- 2017-04-14 WO PCT/US2017/027660 patent/WO2017181031A2/en active Application Filing
- 2017-04-14 MX MX2018012470A patent/MX2018012470A/en unknown
- 2017-04-14 AU AU2017250815A patent/AU2017250815B2/en active Active
- 2017-04-14 WO PCT/US2017/027669 patent/WO2017181039A1/en active Application Filing
- 2017-04-14 JP JP2018554033A patent/JP7116685B2/en active Active
- 2017-04-14 SG SG11201808630WA patent/SG11201808630WA/en unknown
- 2017-04-14 SG SG10202109689Q patent/SG10202109689QA/en unknown
- 2017-04-14 CA CA3020839A patent/CA3020839A1/en not_active Abandoned
- 2017-04-14 TW TW106112586A patent/TW201738272A/en unknown
- 2017-04-14 SG SG10202109691U patent/SG10202109691UA/en unknown
- 2017-04-14 AU AU2017250807A patent/AU2017250807A1/en not_active Abandoned
- 2017-04-14 KR KR1020187032683A patent/KR102444717B1/en active IP Right Grant
- 2017-04-14 EP EP17783252.4A patent/EP3426288A4/en not_active Withdrawn
- 2017-04-14 US US15/487,607 patent/US10202435B2/en active Active
- 2017-04-14 US US15/487,642 patent/US10913783B2/en active Active
- 2017-04-14 SG SG11201808632YA patent/SG11201808632YA/en unknown
- 2017-04-14 CN CN201780036724.3A patent/CN109451728A/en active Pending
- 2017-04-14 JP JP2018554092A patent/JP2019515671A/en not_active Ceased
- 2017-04-14 EP EP17783258.1A patent/EP3426686A4/en active Pending
- 2017-04-14 TW TW106112651A patent/TWI770020B/en active
- 2017-04-14 KR KR1020187032682A patent/KR20190005873A/en not_active Application Discontinuation
- 2017-04-14 CN CN201780036728.1A patent/CN109311977B/en active Active
-
2018
- 2018-10-03 IL IL262092A patent/IL262092B2/en unknown
- 2018-10-03 IL IL262095A patent/IL262095A/en unknown
-
2019
- 2019-02-11 US US16/272,406 patent/US11352409B2/en active Active
-
2020
- 2020-02-11 US US16/787,250 patent/US10954285B2/en active Active
- 2020-02-11 US US16/787,260 patent/US10975135B2/en active Active
- 2020-02-11 US US16/787,313 patent/US10968268B2/en active Active
- 2020-12-15 US US17/122,243 patent/US11938185B2/en active Active
-
2022
- 2022-04-19 US US17/723,674 patent/US20230125604A1/en active Pending
-
2024
- 2024-01-31 AU AU2024200599A patent/AU2024200599A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201808630WA (en) | Humanized anti-pacap antibodies and uses thereof | |
SG11201810640RA (en) | Cd33 specific chimeric antigen receptors | |
SG11201811003PA (en) | Anti-pd-l1 antibodies and uses thereof | |
SG11201900468YA (en) | Anti- gprc5d antibodies, bispecific antigen binding molecules that bind gprc5d and cd3, and uses thereof | |
SG11201806120WA (en) | Ror1 antibody compositions and related methods | |
SG11201808979UA (en) | Novel b7-h3 binding molecules, antibody drug conjugates thereof and methods of use thereof | |
SG11201810697QA (en) | Chimeric antigen receptor and car-t cells that bind bcma | |
SG11201810883TA (en) | Combination therapy | |
SG11201809089QA (en) | Bispecific binding proteins and uses thereof | |
SG11201808783XA (en) | Cd80 variant immunomodulatory proteins and uses thereof | |
SG11201803956UA (en) | Anti-dr5 antibodies and methods of use thereof | |
SG11201900885VA (en) | Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule | |
SG11201903857UA (en) | Antibodies to pd-1 and uses thereof | |
IL268620B1 (en) | Anti-lag3 antibodies, pharmaceutical formulations comprising them and uses thereof for treating cancer | |
SG11201900138TA (en) | Programmed death 1 ligand 1 (pd-l1) binding proteins and methods of use thereof | |
SG11201908131RA (en) | Benzazepine compounds, conjugates, and uses thereof | |
SG11201809627QA (en) | Anti pd-1 and anti-lag3 antibodies for cancer treatment | |
SG11201908023YA (en) | T cell receptors and immune therapy using the same against prame positive cancers | |
SG11201810023QA (en) | Anti-tim-3 antibodies and methods of use thereof | |
SG11201809879WA (en) | Novel antibodies specifically binding to zika virus epitopes and uses thereof | |
SG11201804673WA (en) | Novel anti-claudin antibodies and methods of use | |
SG11201801670YA (en) | Novel peptides and combination of peptides for use in immunotherapy against cll and other cancers | |
SG11201806261XA (en) | Bcma antibodies and use of same to treat cancer and immunological disorders | |
SG11201908650PA (en) | Optimized antibody compositions for treatment of ocular disorders | |
SG11201811292RA (en) | Compositions and methods for the depletion of cells |